Clinical Trial Update: A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial of osimertinib in stage 4 non-small cell lung cancer with uncommon EGFR mutations has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: Duke University | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-10-17